Bharat is competitively positioned to be amongst the global leaders in futuristic manufacturing that leverages living systems. Biomanufacturing can fundamentally transform the global economy from today's consumptive manufacturing paradigm to the one based on regenerative principles. Biomanufacturing refers to the use of engineered microbial, plant, and animal (including human) cells with increasing precision and control to produce commercially important products on scale. These are versatile processes that have the potential to create bio-based products allowing efficient utilisation of resources, in a scalable and costeffective manner with reduced environmental impact. Keeping in view the national priority of steering Bharat on the path of accelerated 'Green Growth', an integrated BioE3 (Biotechnology for Economy, Environment and Employment) Policy for "Fostering High-Performance Biomanufacturing" with an aim to make a green, clean, prosperous, and self-reliant Bharat was released on September 12 at Global Bio-India (GBI) 2024. Let's take a look at how the BioE3 Policy for biomanufacturing is set to transform this landscape.
Bharat's bioeconomy is estimated to be valued around $300 billion by 2030, making it the third largest biotech destination in Asia Pacific and one of the top biotech destinations globally. With COVID-19 providing the industry with a much-needed boost, the country's bioeconomy reached $151 billion in 2023 and witnessed an exponential increase in valuation over the previous 11 years. As one of the top hubs for bioinnovation and biomanufacturing today, Bharat is recognised as a rising sector and a crucial component of the country's economic growth plan, which aims to see its GDP grow to $5 trillion by 2027.
هذه القصة مأخوذة من طبعة BioSpectrum India Oct 2024 من Bio Spectrum.
ابدأ النسخة التجريبية المجانية من Magzter GOLD لمدة 7 أيام للوصول إلى آلاف القصص المتميزة المنسقة وأكثر من 9,000 مجلة وصحيفة.
بالفعل مشترك ? تسجيل الدخول
هذه القصة مأخوذة من طبعة BioSpectrum India Oct 2024 من Bio Spectrum.
ابدأ النسخة التجريبية المجانية من Magzter GOLD لمدة 7 أيام للوصول إلى آلاف القصص المتميزة المنسقة وأكثر من 9,000 مجلة وصحيفة.
بالفعل مشترك? تسجيل الدخول
Amit Agrawal steps in as new Pharmaceuticals Secretary
Amit Agrawal, the Chief Executive Officer (CEO) of the Unique Identification Authority of India (UIDAI), has been appointed as the new Secretary of the Department of Pharmaceuticals, Government of India.
IIT-B joins hands with Tohoku University to offer MTech, PhD dual degree programmes
The Indian Institute of Technology, Bombay (IIT-B) has entered into a Memorandum of Understanding (MoU) with Japan's Tohoku University to launch the IIT Bombay-Tohoku University Joint Academic & Research Programme.
Innovative injectable hydrogel to offer targeted breast cancer therapy
In a multi-institutional research led by researchers from Indian Institute of Technology Guwahati (IIT-G) and Bose Institute Kolkata, an advanced injectable hydrogel has been developed for localised cancer treatment.
Bio-Techne, Waters ink co-marketing agreement for biotherapeutic characterisation
American life sciences company Bio-Techne Corporation, a leader in automated platforms for biotherapeutic characterisation, has announced a co-marketing and co-promotion agreement with Waters Corporation aimed at expanding the reach of advanced biotherapeutic characterisation and development processes.
Nano-formulation of darkness hormone to serve as therapeutic solution for Parkinson's disease
Scientists from Institute of Nano Science and Technology (INST) Mohali have proved that nano-formulation of Melatonin, the hormone produced by the brain in response to darkness, showed improved antioxidative and neuroprotective properties and could be a potential therapeutic solution for Parkinson's disease (PD).
"Govt should facilitate low-interest loans or VC funding specifically for biopharma startups & small enterprises"
\"In a recent development, Nagpur-based biotech company GeNext Genomics (GNG) has joined -hands with Merck Life Science to support the Indian biotech system, particularly in the area of biomanufacturing, which is garnering more attention after the approval of the BioE3 policy.Supriya Kashikar, Founder & Chief Executive Officer, GeNext Genomics shares her views with BioSpectrum on the growth of biomanufacturing sector in India, and how the company plans to play a relevant role in this aspect.
Redcliffe Labs reinforces strategic leadership as Aditya Kandoi steps into CEO role, Dheeraj Jain as Chairman
Redcliffe Labs, a purpose-driven pan-India omnichannel diagnostics service provider, has announced a strategic leadership transition.
Zyla Health on-boards Rohit Boda as Advisor
Gurugram-based Zyla Health, a care management platform, has announced the onboarding of renowned industry leader, Rohit Boda, to the Board of Advisors.
Claypond Capital appoints Shravan Subramanyam to lead medtech platform
Claypond Capital, the family investment office of Dr Ranjan Pai, has announced the appointment of Dr Shravan Subramanyam as the head of its medical technology platform.
How AI Innovations at GCCs Solidifying India's Position in Global Life Sciences Industry
India's life sciences sector is undergoing a major transformation, led by the expansion of Global Capability Centres GCCs). These centres, which serve as strategic hubs for multinational companies in pharmaceuticals, biotechnology, and healthcare, are strengthening India's role in the global life sciences landscape. Currently, there are over 95 life sciences GCCs in India, employing approximately 280,000 professionals. By 2030, this number is projected to reach 160 GCCs and around 420,000 employees. Advancements in artificial intelligence AI) are central to this transformation, driving innovation across drug discovery and clinical research. India's life sciences GCCs have evolved from operational support centres to world-class R&D engines, leveraging India’s robust talent pool, advanced technology adoption, and cost advantages. These GCCs are driving the future of Al-powered drug discovery and clinical research. Let’s explore further.
